机构:[1]State Key Laboratory of Virology,Department Gynecology,Cancer Biology Research Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan, Hubei 430030, P. R. China华中科技大学同济医学院附属同济医院[2]Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE),Hubei Province Engineering and Technology Research Center ,for Fluorinated Pharmaceuticals,Wuhan University School of Pharmaceutical Sciences,Wuhan 430071, China[3]Innovative Institute of Chinese Medicine and Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu, Sichuan 611137, China[4]Department of Orthopedics Trauma and Microsurgery,Zhongnan Hospital of Wuhan University,Wuhan, Hubei 430071, China
Osteosarcoma is an aggressive tumor of mesenchymal origin that is more likely to spread to the lung than others, with a major impact on patients' prognosis. The optimal imaging method that can reliably detect or exclude pulmonary metastases from osteosarcoma is still scarce. Herein, two homologous types of fluorescent probes CH1055-PEG-PT and CH1055-PEG-Affibody, which show highly promising results for targeting imaging of osteosarcoma and its lung metastasis, respectively, are designed and synthesized. It is found that the NIR-II imaging quality of CH1055-PEG-PT is far superior to that of computed tomography for the early in vivo 143B tumor imaging, and this probe-guided surgery for accurate resection of 143B tumor is further performed. The high-resolution visualization of primary and micrometastatic lung lesions of osteosarcoma by using CH1055-PEG-Affibody is also demonstrated. Therefore, the attractive imaging properties of CH1055-PEG-PT and CH1055-PEG-Affibody, including high levels of uptakes, and high spatial and temporal resolution, open up opportunities for molecular imaging and clinical translation of osteosarcoma and its lung metastasis in the unique second near-infrared window.
基金:
NSFCNational Natural Science Foundation of China [81773674, 81573383]; Natural Science Foundation of Hubei ProvinceNatural Science Foundation of Hubei Province [2017CFB641, 2017CFA024, 2017CFB711, 2016ACA126]; Applied Basic Research Program of Wuhan Municipal Bureau of Science and Technology [2019020701011429, 2019020701011436]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities; Tibet Autonomous Region Science and Technology Plan Project Key Project [XZ201901-GB-11]; Chengdu University of Traditional Chinese Medicine [CZYJC1903]; Health Commission of Hubei Province Scientific Research Project [WJ2019M177, WJ2019M178]
第一作者机构:[1]State Key Laboratory of Virology,Department Gynecology,Cancer Biology Research Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan, Hubei 430030, P. R. China[2]Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE),Hubei Province Engineering and Technology Research Center ,for Fluorinated Pharmaceuticals,Wuhan University School of Pharmaceutical Sciences,Wuhan 430071, China[3]Innovative Institute of Chinese Medicine and Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu, Sichuan 611137, China
共同第一作者:
通讯作者:
通讯机构:[2]Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE),Hubei Province Engineering and Technology Research Center ,for Fluorinated Pharmaceuticals,Wuhan University School of Pharmaceutical Sciences,Wuhan 430071, China[3]Innovative Institute of Chinese Medicine and Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu, Sichuan 611137, China
推荐引用方式(GB/T 7714):
Hui Zhou,Wanrong Yi,Anguo Li,et al.Specific Small-Molecule NIR-II Fluorescence Imaging of Osteosarcoma and Lung Metastasis[J].ADVANCED HEALTHCARE MATERIALS.2020,9(1):doi:10.1002/adhm.201901224.
APA:
Hui Zhou,Wanrong Yi,Anguo Li,Bo Wang,Qihang Ding...&Xuechuan Hong.(2020).Specific Small-Molecule NIR-II Fluorescence Imaging of Osteosarcoma and Lung Metastasis.ADVANCED HEALTHCARE MATERIALS,9,(1)
MLA:
Hui Zhou,et al."Specific Small-Molecule NIR-II Fluorescence Imaging of Osteosarcoma and Lung Metastasis".ADVANCED HEALTHCARE MATERIALS 9..1(2020)